← Back to Clinical Trials
Recruiting NCT06526065

Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

◆ AI Clinical Summary

This study is developing a simple blood test or diagnostic tool to help doctors identify which patients with diffuse large B cell lymphoma (DLBCL) are at highest risk of their cancer returning after standard chemotherapy treatment. By catching high-risk patients early, doctors can plan better treatment strategies for them.

Key Objective: The trial aims to create an accurate and affordable prognostic tool that can reliably predict which DLBCL patients will have poor outcomes with standard R-CHOP chemotherapy, enabling personalized treatment planning.

Who to Consider: Patients with newly diagnosed diffuse large B cell lymphoma who are being considered for standard R-CHOP or similar chemotherapy should consider enrolling.

Trial Parameters

Condition DLBCL - Diffuse Large B Cell Lymphoma
Sponsor University Medical Center Goettingen
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age 18 Years
Max Age 85 Years
Start Date 2024-06-20
Completion 2026-06-01
Interventions
no intervention

Brief Summary

The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.

Eligibility Criteria

Inclusion Criteria: 1. Histological diagnosis of DLBCL\&LBCL 2. Planned treatment with guideline-based first-line therapy 3. Patient's consent 4. All genders, Patient age ≥ 18 years 5. Ability to consent Exclusion Criteria: 1. Treatment with R-CHOP/-like regimens already started 2. Relationship of dependence/ direct employment with the investigator 3. Active HIV-infection 4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)

Related Trials